igrelimogene litadenorepvec
AXP000009.2 · Oncolytic virus
- Platform
- adenovirus (Ad5/3 chimera, E2F promoter, Delta-24)
- Originator
- TILT Biotherapeutics
- Sponsor
- TILT Biotherapeutics
Names
| Name | Type | Source |
|---|---|---|
| igrelimogene litadenorepvec | preferred name, INN | curator, ncit |
| Ad5/3-E2F-d24-hTNFa-IRES-hIL2 | code | ncit |
| TILT-123 | code | ncit |
Virus
- Role
- Oncolytic
- Family
- Adenoviridae
- Virus
- human adenovirus 5 (NCBI Taxonomy 28285)
- Strain
- Ad5/3 chimera
- Replication
- conditionally replicating
- Modifications
- E2F promoter drives E1A; 24-bp E1A CR2 deletion; Ad3 fiber knob
- Transgenes
- TNF, IL2
- Route
- intratumoral, intravenous, intraperitoneal
- Source
- evidence
Cross-references
- NCI Thesaurus
- C175454
- FDA UNII
- 484TEV85XS
Approvals
No regulatory approval recorded.
Clinical trials (6)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT06961786 | TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of Melanoma | Active not recruiting | Phase 1 | 2025-06-25 | 2026-11 | 9 | Metastatic Melanoma |
| NCT06125197 | Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer | Active not recruiting | Phase 1 | 2024-07-23 | 2026-01-30 | 22 | Lung Cancer |
| NCT05222932 | Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1 | Active not recruiting | Phase 1 | 2023-03-08 | 2026-12 | 15 | Head and Neck Squamous Cell Carcinoma; Melanoma |
| NCT05271318 | Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer. | Active not recruiting | Phase 1/2 | 2022-05-17 | 2027-03 | 29 | Platinum-Refractory Fallopian Tube Carcinoma; Platinum-Refractory Primary Peritoneal Carcinoma; Platinum-Resistant Fallopian Tube Carcinoma; Platinum-Resistant Primary Peritoneal Carcinoma; Platinum-Sensitive Fallopian Tube Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin; Platinum-Sensitive Ovarian Cancer in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin; Platinum-Sensitive Primary Peritoneal Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin; Platinum-refractory Ovarian Carcinoma; Platinum-resistant Ovarian Cancer |
| NCT04695327 | TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 Monotherapy | Completed | Phase 1 | 2021-01-11 | 2025-09-03 | 32 | Solid Tumor |
| NCT04217473 | TNFalpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 During TIL Treatment of Advanced Melanoma | Completed | Phase 1 | 2020-02-26 | 2023-12-12 | 17 | Metastatic Melanoma |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41566775 | Dyslipidemia-associated natural IgM improves oncolytic virus TILT-123 efficacy through antibody-dependent enhancement in solid tumors. | Molecular therapy : the journal of the American Society of Gene Therapy | 2026 | cited by trial NCT04217473 |
| PMID 42136030 | Fully intravenous split-dose administration of the oncolytic adenovirus TILT-123 in advanced solid tumors. | Molecular therapy : the journal of the American Society of Gene Therapy | 2026 | name in title: TILT-123 |
| PMID 42624531 | Immune-cytokine signature predicts survival in patients with advanced melanoma treated with oncolytic adenovirus TILT-123 and chemotherapy and IL-2-free adoptive TIL therapy. | Journal for immunotherapy of cancer | 2026 | cited by trial NCT04217473 |
| PMID 39870491 | Transient lymphocyte count decrease correlates with oncolytic adenovirus efficacy in humans: mechanistic and biomarker findings from TUNIMO phase I trial. | Journal for immunotherapy of cancer | 2025 | name in abstract: igrelimogene litadenorepvec |
| PMID 39910037 | The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial. | Nature communications | 2025 | name in title: TILT-123 |
| PMID 40107242 | Safety and efficacy of combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus TILT-123 in metastatic melanoma. | Cell reports. Medicine | 2025 | name in title: TILT-123 |
| PMID 40211048 | Single-cell profiling of peripheral blood mononuclear cells from patients treated with oncolytic adenovirus TILT-123 reveals baseline immune status as a predictor of therapy outcomes. | Cancer gene therapy | 2025 | name in title: TILT-123 |
| PMID 38546220 | Safety, Efficacy, and Biological Data of T-Cell-Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2024 | name in title: TILT-123 |
| PMID 39506856 | Single intravenous administration of oncolytic adenovirus TILT-123 results in systemic tumor transduction and immune response in patients with advanced solid tumors. | Journal of experimental & clinical cancer research : CR | 2024 | cited by trial NCT04217473 |
| PMID 33513935 | Cytokine-Coding Oncolytic Adenovirus TILT-123 Is Safe, Selective, and Effective as a Single Agent and in Combination with Immune Checkpoint Inhibitor Anti-PD-1. | Cells | 2021 | cited by trial NCT04217473 |
| PMID 32322662 | Comparison of Clinically Relevant Oncolytic Virus Platforms for Enhancing T Cell Therapy of Solid Tumors. | Molecular therapy oncolytics | 2020 | cited by trial NCT04217473 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41957950 | Alistipes and Eggerthella shape the response to oncolytic adenovirus therapy in mice and humans through short-chain fatty acid metabolism. | Oncoimmunology | 2026 | name in abstract: igrelimogene litadenorepvec |
| PMID 42970481 | Effects of Concomitant Medications on Clinical and Immunological Outcomes of Cancer Patients Treated With Oncolytic Adenoviruses. | International journal of cancer | 2026 | name in abstract: igrelimogene litadenorepvec |
| PMID 42982510 | Antiviral humoral immunity as biomarker and effector in oncolytic adenovirus TILT-123 therapy. | Journal for immunotherapy of cancer | 2026 | name in title: TILT-123 |
| PMID 41029444 | Novel tumor-infiltrating lymphocytes therapy in solid tumors: latest updates from 2025 ASCO annual meeting. | Experimental hematology & oncology | 2025 | name in abstract: TILT-123 |
| PMID 39801682 | Durable complete response after combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus (TILT-123) in a patient with metastatic mucosal melanoma. | Immuno-oncology technology | 2024 | name in title: TILT-123 |
| PMID 36817448 | Development of a Syrian hamster anti-PD-L1 monoclonal antibody enables oncolytic adenoviral immunotherapy modelling in an immunocompetent virus replication permissive setting. | Frontiers in immunology | 2023 | name in abstract: TILT-123 |
| PMID 37546696 | Effective intravenous delivery of adenovirus armed with TNFα and IL-2 improves anti-PD-1 checkpoint blockade in non-small cell lung cancer. | Oncoimmunology | 2023 | name in abstract: TILT-123 |
| PMID 35997357 | Effective Combination Immunotherapy with Oncolytic Adenovirus and Anti-PD-1 for Treatment of Human and Murine Ovarian Cancers. | Diseases (Basel, Switzerland) | 2022 | name in abstract: Ad5/3-E2F-d24-hTNFa-IRES-hIL2 |
| PMID 33922052 | Systemic Delivery of Oncolytic Adenovirus to Tumors Using Tumor-Infiltrating Lymphocytes as Carriers. | Cells | 2021 | name in abstract: Ad5/3-E2F-d24-hTNFa-IRES-hIL2 |
| PMID 31940588 | Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity. | Journal for immunotherapy of cancer | 2020 | name in abstract: Ad5/3-E2F-d24-hTNFa-IRES-hIL2 |
| PMID 32225009 | TNFa and IL2 Encoding Oncolytic Adenovirus Activates Pathogen and Danger-Associated Immunological Signaling. | Cells | 2020 | name in abstract: TILT-123 |
| PMID 32923123 | Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition. | Oncoimmunology | 2020 | name in abstract: Ad5/3-E2F-d24-hTNFa-IRES-hIL2 |
| PMID 29721366 | TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade. | Oncoimmunology | 2018 | name in abstract: TILT-123 |
| PMID 30017877 | Adenovirus Coding for Interleukin-2 and Tumor Necrosis Factor Alpha Replaces Lymphodepleting Chemotherapy in Adoptive T Cell Therapy. | Molecular therapy : the journal of the American Society of Gene Therapy | 2018 | name in abstract: TILT-123 |
| PMID 30569015 | Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus. | Molecular therapy oncolytics | 2018 | name in abstract: TILT-123 |
| PMID 28345026 | Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy. | Molecular therapy oncolytics | 2017 | name in abstract: Ad5/3-E2F-d24-hTNFa-IRES-hIL2 |
Notes
Construct name Ad5/3-E2F-d24-hTNFa-IRES-hIL2 from NCIt; transgenes TNF-alpha and IL-2. Transgenes moved from targets to virus.tsv (spec 0.2).
How to cite
igrelimogene litadenorepvec (AXP000009.2). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000009.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.